** Shares of regenerative medicine company Orthocell OCC.AX rise 7.8% to A$1.390, set for biggest one-day gain since April 10
** Co says it has received regulatory approval to commence sales for its nerve repair product, Remplir, from the Food and Drug Administration in Thailand
** Stock on track for third consecutive session of gains
** Stock up 2.6% YTD, including current session's moves
(Reporting by Manasi Dasa in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。